Investors were reminded Monday that the healthcare sector remains this year’s premiere destination for large-scale mergers and acquisitions activity when Israel’s Teva Pharmaceuticals (NYSE: TEVA) agreed to pay $40.5 billion in cash and stock for Allergan PLC (NYSE: AGN)'s generic drugs unit.
That does not represent the end of pharmaceuticals M&A activity. It probably doesn’t and there are several exchange traded funds that should benefit from more consolidation in the pharmaceuticals industry.
The $409 million Market Vectors Pharmaceutical ETF (NYSE: PPH) is a good place to look for potential pharma buyers and sellers. Home to 26 stocks, PPH features plenty of buyers and potential buyers, including a 5.4 percent weight to Teva and an almost 5.5 percent weight to Dow component Pfizer Inc. (NYSE: PFE), a company that has been champing at the bit ...
/www.benzinga.com/trading-ideas/long-ideas/15/07/5710517/etfs-for-the-next-pharma-takeover-candidates alt=ETFs For The Next Pharma Takeover Candidates>Full story available on Benzinga.com
More...